Is There Room for New Drugs in the Treatment of Advanced Heart Failure: SGLT2i?
- 29 June 2022
- journal article
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 195-197
Abstract
Over the last years, we have witnessed the inclusion of the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for the treatment of patients with heart failure. Drugs in this group share the fact that they are able to inhibit glucose transport in the proximal tubule and thus promote glycosuria and blood glucose reduction in patients with diabetes. Other effects of these medications include increasing diuresis and natriuresis, lowering blood pressure, stimulating erythropoiesis, improving cardiac energy metabolism, reducing inflammation, inhibiting the [...] Over the last years, we have witnessed the inclusion of the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for the treatment of patients with heart failure. Drugs in this group share the fact that they are able to inhibit glucose transport in the proximal tubule and thus promote glycosuria and blood glucose reduction in patients with diabetes. Other effects of these medications include increasing diuresis and natriuresis, lowering blood pressure, stimulating erythropoiesis, improving cardiac energy metabolism, reducing inflammation, inhibiting theKeywords
This publication has 11 references indexed in Scilit:
- SGLT-2 inhibitors in frail patients with heart failureInternational Journal of Cardiology, 2022
- A Meta-Analysis of the Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure and Preserved Ejection FractionThe American Journal of Cardiology, 2022
- SGLT2 inhibitor therapy and pulmonary artery pressure in patients with chronic heart failure—further evidence for improved hemodynamics by continuous pressure monitoringClinical Research in Cardiology, 2021
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With Heart Failure and Preserved Ejection Fraction: EMPEROR-Preserved TrialCirculation, 2021
- Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HFEuropean Heart Journal, 2021
- Effects of SGLT2 inhibitors on cardiovascular, renal, and major safety outcomes in heart failure: A meta-analysis of randomized controlled trialsInternational Journal of Cardiology, 2021
- Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) InhibitorsJACC: Basic To Translational Science, 2020
- Dapagliflozin and Cardiovascular Outcomes in Type 2 DiabetesNew England Journal of Medicine, 2019
- Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesNew England Journal of Medicine, 2017
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesNew England Journal of Medicine, 2015